Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy

William A. Hall, Colleen A. Lawton, Ashesh B. Jani, Alan Pollack, Felix Y. Feng

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself. We highlight the potential use and limitations of these biomarkers and present possible future directions for biomarker investigation.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalSeminars in Radiation Oncology
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Prostatic Neoplasms
Radiotherapy
Biomarkers
Tumor Biomarkers
Neoplasms
Urine
Biopsy
Serum
Direction compound

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. / Hall, William A.; Lawton, Colleen A.; Jani, Ashesh B.; Pollack, Alan; Feng, Felix Y.

In: Seminars in Radiation Oncology, Vol. 27, No. 1, 01.01.2017, p. 11-20.

Research output: Contribution to journalReview article

Hall, William A. ; Lawton, Colleen A. ; Jani, Ashesh B. ; Pollack, Alan ; Feng, Felix Y. / Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. In: Seminars in Radiation Oncology. 2017 ; Vol. 27, No. 1. pp. 11-20.
@article{181d327286934d2589f9d915cd487320,
title = "Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy",
abstract = "Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself. We highlight the potential use and limitations of these biomarkers and present possible future directions for biomarker investigation.",
author = "Hall, {William A.} and Lawton, {Colleen A.} and Jani, {Ashesh B.} and Alan Pollack and Feng, {Felix Y.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.semradonc.2016.09.001",
language = "English (US)",
volume = "27",
pages = "11--20",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy

AU - Hall, William A.

AU - Lawton, Colleen A.

AU - Jani, Ashesh B.

AU - Pollack, Alan

AU - Feng, Felix Y.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself. We highlight the potential use and limitations of these biomarkers and present possible future directions for biomarker investigation.

AB - Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself. We highlight the potential use and limitations of these biomarkers and present possible future directions for biomarker investigation.

UR - http://www.scopus.com/inward/record.url?scp=85006751493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006751493&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2016.09.001

DO - 10.1016/j.semradonc.2016.09.001

M3 - Review article

C2 - 27986207

AN - SCOPUS:85006751493

VL - 27

SP - 11

EP - 20

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 1

ER -